Status:
UNKNOWN
COVID-19. CT-Scan Modeling in COVID19 Sequelae
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 infection manifests in its severe form as acute alveolo-interstitial and vascular pneumonitis. However, long-term outcome remains unknown. A progression to fibrosing pneumonia could affect 10...
Detailed Description
"The SILICOVILUNG project is based on the retrospective analysis of pulmonary CT images of patients followed after severe COVID pneumonitis at the Avicenne APHP hospital (Bobigny, France). CT series w...
Eligibility Criteria
Inclusion
- Patients who are informed and have not objected to participating in the research.
- Patients with initial severe pulmonary disease \[COVID + PCR, O² supplementation \> 3l/min O²; \> 25% CT lesions visible on the CT scan at the time of hospitalization, no pulmonary embolism and no mechanical ventilation\].
- Fifty files will be selected according to the types of short-term sequelae observed during the first check-up at 2-4 months: 30 on an aspect of alveolar and interstitial CT scan lesions associated or not with respiratory functional impairment; 20 others will be selected on the existence of significant functional impairment (DLCO \<65% of the theoretical value) without or with few CT abnormalities (situations where sequelae of pulmonary vascularization would potentially predominate).
Exclusion
- Patients under 18 years old.
- Patients with a history of. of interstitial lung disease or COPD.
- Patients under guardianship.
- Patients receiving state medical aid.
Key Trial Info
Start Date :
February 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04747769
Start Date
February 3 2021
End Date
October 1 2021
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Avicenne APHP
Bobigny, France, 93000